arge, prospective epidemiological studies have shown that elevated triglyceride levels are associated with increased coronary artery disease (CAD) risk, 1,2 independent of lowdensity lipoprotein cholesterol (LDL-C) and high-density lipoprotein (HDL) cholesterol.
corroborated causality by directly linking genetic variation in APOC3 to CAD risk. 11, 12 Collectively, these findings have spurred the development of apoC-III-lowering therapies, of which an antisense inhibitor of APOC3 messenger RNA has been shown to potently reduce both plasma apoC-III and triglyceride levels. 4, 5 In view of the intricate relationship between apoC-III and several proatherogenic lipoprotein fractions and its recent implication in inflammatory pathways, 13 it remains to be established which factors mediate the detrimental impact of elevated apoC-III on CAD risk. Therefore, we assessed the association between apoC-III levels, detailed lipoprotein analyses, inflammatory markers, and CAD risk in a large prospective nested case-control study.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Plasma apoC-III measurements were available for 2711 participants, 832 cases and 1879 controls. Baseline characteristics for CAD cases and controls are listed in Table 1 . Despite partial loss of matching because of plasma sample availability, age and sex were similar between groups. The prevalence of traditional cardiovascular risk factors was higher in cases compared with controls: more active smokers, higher body mass index (BMI), elevated blood pressure, total cholesterol, LDL-C, triglycerides, and apoB levels, whereas HDL cholesterol and apo AI levels were lower in cases. ApoC-III levels were indeed higher in cases compared with controls. Figure 1 shows the distribution of apoC-III and triglyceride levels among cases and controls, showing a shifted distribution toward higher apoC-III and triglyceride levels among cases. Table 2 and Table I in the online-only Data Supplement show baseline characteristics according to apoC-III quintiles. Age was slightly lower, and there were fewer males in the highest quintile compared with the lowest. For a complete overview, baseline characteristics for males and females separately are provided in Tables II and III in the online-only Data Supplement. Higher apoC-III levels were associated with increased BMI, use of lipid-lowering drugs, use of antihypertensive drugs, and increased systolic and diastolic blood pressure. Triglyceride levels were most profoundly associated with apoC-III quintiles.
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ApoC-III and Lipid Metabolism Parameters
At baseline, apoC-III levels were correlated with total cholesterol (r=0.23; P<0.001), LDL-C (r=0.13, P<0.001) and triglycerides (r=0.39; P<0.001; Table 3 ). ApoC-III levels were correlated with VLDL particle number and size (r=0.24 and r=0.27; P<0.001) and with large VLDL/chylomicron-sized particle number (r= 0.39; P<0.001). There was also a positive correlation with IDL particle number (r=0.23; P<0.001) and similarly LDL particle number (r=0.26; P<0.001) and an inverse correlation with LDL particle size (r=−0.22; P<0.001). Similar correlations were found for LDL parameters measured by gradient gel electrophoresis. Furthermore, apoC-III levels were positively correlated with apolipoprotein AV levels (r=0.21; P<0.001) and inversely correlated with LPL mass (r=−0.13, P<0.001). Sex-specific Spearman correlations for apoC-III and lipid and nonlipid variables are given in Table  IV in the online-only Data Supplement and are similar to the overall group.
In line with the correlations with triglyceride-related parameters, apoC-III levels were correlated with HDL particle number (r=0.20; P<0.001) and inversely correlated with HDL particle size (r=−0.23; P<0.001.) There was a weak positive correlation between apoC-III and cholesterol efflux capacity (r=0.08; P<0.001), lecithin-cholesterol acyltransferase mass (r=0.13; P<0.001) but no correlation with CETP (Cholesteryl Ester Transfer Protein) mass (r=−0.01; P=0.64). Finally, apoC-III levels were weakly correlated with high-sensitivity C-reactive protein levels (r=0.15; P<0.001). All correlations were additionally tested in a linear regression model adjusted for age, sex, BMI, current smoking, systolic blood pressure, history of diabetes mellitus, lipid-lowering, and antihypertensive drug use, which did not attenuate significance importantly.
Further analysis of apoC-III levels by quintiles and lipoprotein particle numbers and size measured by nuclear magnetic resonance spectroscopy shows a progressive increase in all sizes of VLDL particles, IDL, and small dense LDL, but a decrease for large LDL, all P<0.001 for trend Figure 2 ; detailed particle numbers and size per apoC-III quartile are provided in Table I in the online-only Data Supplement.
ApoC-III Levels and CAD Risk
In a logistic regression analysis, adjusted for age and sex, the odds ratio for incident CAD was 1.91 (95% confidence interval [CI], 1.48-2.48) for highest quintile apoC-III compared with lowest quintile (Figure 3 ; Table V in the online-only Data Supplement). After adjustment for cardiovascular risk factors (age, sex, BMI, current smoking, diabetes mellitus, systolic blood pressure, lipid-lowering, and antihypertensive drug use), apoC-III levels remained significantly associated with CAD risk (odds ratio, 1.47; 95% CI, 1.11-1.94). This association was attenuated but remained significant after further adjustment for LDL-C (odds ratio, 1.35; 95% CI, 1.01-1.81) or HDL cholesterol (odds ratio, 1.41; 95% CI, 1.05-1.88), but lost significance after adjustment for triglycerides (odds ratio, 1.17; 95% CI, 0.87-1.58; Table 4 ).
In subgroup analysis, we found that apoC-III levels were not as strongly associated with CAD risk in subjects with LDL-C lower than the median compared with subjects with LDL-C over the median ( Figure I in the online-only Data Supplement). Furthermore, apoC-III levels were not significantly associated with CAD risk in subjects with triglycerides lower than the median (Figures I and II in the online-only Data Supplement). There was no important difference in CAD risk between males and females.
ApoC-III Mediation Analysis
Next, we explored which of the lipoprotein subfractions explained part of the association between apoC-III and CAD risk (Table 4) . We found that plasma triglyceride levels (55%) Nuclear magnetic resonance spectroscopy measured lipoprotein subparticle numbers per apolipoprotein C-III (apoC-III) quintile. Bars display mean particle numbers in nmol/L and corresponding 95% confidence interval (CI). A, Very-low-density lipoprotein (VLDL; small, medium, large/chylomicron) particle numbers, total bar height represents total VLDL particle number. B, Intermediate-density lipoprotein (IDL) particle numbers per apoC-III quintile. C, Low-density lipoprotein (LDL; small and large) particle number per apoC-III, total bar height represents total LDL particle number. P value for trend <0.001 for all (sub)particle number associations.
explained a major part of the association between apoC-III and CAD risk, followed by apoB levels (31%). VLDL and LDL particle numbers both explained 24%, of the association between apoC-III and CAD risk, and interestingly, the association observed for LDL particles was fully attributable to small dense LDL particles (24%), independent of large LDL particle numbers. Similar effect sizes were found for the multivariable-adjusted model, independent from BMI, smoking status, diabetes mellitus, systolic blood pressure, and blood pressurelowering and lipid-lowering drugs. Similar results were found for the difference and product method and for apoC-III as a continuous variable (data are shown for difference method and apoC-III quintiles).
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Triglyceride Levels and Calculated Remnant Cholesterol Levels
In recent literature, triglyceride levels are increasingly acknowledged as a biomarker for the cholesterol content of TRL, known as remnant cholesterol, which is understood to be the relevant contributor to atherosclerosis. 15 Because LDL-C in our study is calculated using the Friedewald formula, both parameters are mathematically related, which is illustrated by the strong correlation between triglycerides and remnant cholesterol levels (R 2 =0.99; P<0.001). However, to be as thorough and complete as possible in our analyses, we did include remnant cholesterol and found identical associations for apoC-III and triglyceride or remnant cholesterol levels.
Discussion
This large, prospective study demonstrates that elevated apoC-III levels are associated with a significantly increased risk of CAD. Furthermore, the risk of elevated apoC-III levels was strongly and quantitatively associated with several parameters of TRL, small LDL particles, and inflammation. This study represents the largest study to date to substantiate the association between apoC-III plasma levels and CAD risk, in terms of total subjects studied and CAD case numbers, and provides another level of epidemiological evidence to support the genetic data of apoC-III as a potential target of therapy. 5 Our results are in line with previous reports that report on the association of apoC-III with CAD risk [16] [17] [18] and, recently, with atherosclerotic burden in diabetics. 19 In those studies, apoC-III has been shown to correlate strongly with plasma triglyceride levels in populations with a wide variation in absolute plasma triglyceride levels. 4, 5, 17 In our study, the correlation was weaker, which perhaps can be explained by the relatively restricted range of triglyceride values and low incidence of diabetes mellitus observed in this normal population. Nevertheless, we found that subjects with higher apoC-III levels had higher VLDL particle numbers and larger VLDL mean particle size and increased IDL particle numbers. Previous tracer kinetic studies 9,20 support a role for apoC-III in inhibiting the rate of clearance of VLDL from plasma, which is suggested to be consistent with inhibition of LPL-mediated hydrolysis and/or inhibition of hepatic uptake of TRL. In particular, the presence of apoC-III on light LDL was associated with enhanced conversion to dense LDL. 9 These latter observations are perhaps related to our observation that high apoC-III levels are associated with a shift toward predominantly small dense LDL particles. Alternatively, increased levels of TRL particles in hypertriglyceridemia increases the transfer of triglyceride from VLDL to LDL in exchange for cholesteryl ester, mediated by CETP, and in turn the triglycerides enriched in LDL are hydrolyzed via hepatic lipase, further contributing to small dense LDL. 21 Similar findings were reported in a smaller genetic study of loss-of-function APOC3 variants that found a clear correlation with VLDL, IDL, and LDL subfractions. 10 The mechanism linking apoC-III and CAD risk is poorly understood. Triglycerides per se are unlikely causal in atherosclerosis development as triglycerides can be degraded by most cell types and do not accumulate in atherosclerotic plaques. However, VLDL and remnant lipoproteins, such as small VLDL and IDL, do accumulate in the arterial intima, where ≤40% of particles consist of VLDL and VLDL remnant-sized lipoproteins. 22 Macrophages within the arterial intima secrete LPL, which can further metabolize these TRLs to even smaller remnants, which can then be taken up by macrophages, delivering their cholesterol content and generating foam cells. 23, 24 Thus, hypertriglyceridemia should be regarded as a marker of the cholesterol content in TRLs (VLDL+IDL), so-called remnant cholesterol. Indeed, calculated remnant cholesterol and genetic variants determining remnant cholesterol levels are strongly associated with CAD risk. 15 Using mediation analysis in our study, we found that a substantial part of the increased CAD risk associated with apoC-III levels could be attributed to the effect of TRL remnant particle concentrations. Despite the strong effect on TRLs, part of the association of apoC-III and CAD risk could also be explained by the effect of LDL particle concentration, which was fully attributable to small dense LDL particles, well-known biomarkers of increased CAD risk. 25, 26 Last, we show that apoC-III is correlated with higher highsensitivity C-reactive protein levels in our study. Interestingly, elevated remnant cholesterol levels, driven by genetics, are also associated causally with low-grade inflammation. 15 Such a lowgrade inflammatory state, as assessed by elevated high-sensitivity C-reactive protein, is associated with increased CAD risk. 27 Although we show strong correlations between apoC-III levels, CAD risk and lipoprotein particle concentrations, it should be stressed that this does not necessarily imply causality, and confirmation by intervention studies is warranted. However, we did adjust for BMI and other risk factors in our analyses, and genetic studies of APOC3 loss-of-function variants do support our findings on lipoprotein particles.
10 HbA1c (glycated hemoglobin) levels were only available for 40% of the study cohort and were therefore not included in the multivariable-adjusted regression models. We did adjust for diabetes mellitus status but cannot rule out that the effect of apoC-III on glucose metabolism might be underestimated in our study.
Currently, apoC-III-targeted therapies are in development of which the second-generation antisense oligonucleotide volanesorsen has shown the most promise to date. In 57 high triglyceride patients, 300 mg of weekly volanesorsen resulted in apoC-III reductions up to ≈−80%, which translated to equally potent lowering of plasma triglyceride (≤−70.9%) and VLDL-C (≤−70%). 5 The strong association between apoC-III, TRLs, and CAD in our study holds promise for the potential of these therapies to lower CAD risk, which will need to be tested in future cardiovascular outcome trials. However, our study also indicates that the association of apoC-III and CAD risk is not as strong in subjects with lower LDL-C, supporting LDL-C-lowering therapies as the initial CAD risk modifying strategy, as is advocated in current guidelines.
Conclusions
Our results demonstrate the robust association of elevated plasma apoC-III levels with CAD risk, independent of traditional cardiovascular disease risk factors. Furthermore, we show that elevated apoC-III levels are associated with an unfavorable lipoprotein profile, characterized by increased VLDL and IDL particles, and a redistribution of LDL particles toward increased small dense LDL particles and low-grade inflammation. Mediation analysis indicated that the association between apoC-III and CAD risk is likely explained by apoC-III's association with triglyceride elevation (triglyceride, VLDL, and IDL particles) and small dense LDL. Odds ratios and corresponding 95% confidence intervals for coronary artery disease for highest quintile compared with lowest apoC-III quintile. + parameter indicates odds ratio for apoC-III (Q5 vs Q1) additionally adjusted for + parameter. Percentage explained indicates the proportion of the association of apoC-III with CAD risk that is explained by the mediator. P value for likelihood ratio test between models. Apo indicates apolipoprotein; CAD, coronary artery disease; CRP, C-reactive protein; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; NMR, nuclear magnetic resonance; ns, nonsignificant; and VLDL, very-low-density lipoprotein.
Model 1: ApoC-III highest vs lowest quintile, adjusted for age, and sex. Model 2: Additionally adjusted for body mass index, current smoking, diabetes mellitus, systolic blood pressure lipid-lowering medication, and antihypertensive medication use.
